Real-World Insurance Claims Analysis of Venous Thromboembolism in Japanese Patients with Inflammatory Bowel Disease

被引:2
|
作者
Fujiya, Mikihiro [1 ]
Kawaguchi, Tsutomu [2 ]
Arai, Shoko [2 ]
Isogawa, Naoki [3 ]
Hiro, Shintaro [3 ]
Matsumoto, Fumihiro [2 ]
Yamaguchi, Satoshi [2 ,4 ]
Yoshii, Noritoshi [2 ]
Nakamura, Mashio [5 ]
Matsuoka, Katsuyoshi [6 ]
机构
[1] Asahikawa Med Univ, Dept Med, Div Gastroenterol & Hematol Oncol, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan
[2] Pfizer Japan Inc, Immunol & Inflammat Med Affairs, Shinjuku Culture Quint Bldg 3-22-7 Yoy Shibuya Ku, Tokyo 1518589, Japan
[3] Pfizer R&D Japan, Biometr & Data Management, Shinjuku Culture Quint Bldg 3-22-7 Yoy Shibuya Ku, Tokyo 1518589, Japan
[4] Int Univ Hlth & Welf, Tokyo, Japan
[5] Hidamarinooka Nakamura Med Clin, Dept Internal Med Pediat & Cardiol, 7-1510 Hidamarinooka, Kuwana 5110867, Japan
[6] Toho Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Sakura Med Ctr, Sakura, Chiba 2850841, Japan
关键词
Incidence; Inflammatory bowel diseases; Japan; Risk factors; Venous thromboembolism; RISK-FACTORS; PREVENTION; PREVALENCE; THROMBOSIS; EVENTS;
D O I
10.1007/s10620-022-07388-w
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Inflammatory bowel disease (IBD), which encompasses both ulcerative colitis (UC) and Crohn's disease (CD), is a risk factor for venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Aim To investigate the incidence of, and risk factors for, VTE in patients with IBD in Japan. Methods This was a retrospective, non-interventional study in patients with IBD from the Japan Medical Data Center claims database. Incidence rates (IRs; unique patients with events per 100 patient-years) were calculated for VTE, DVT, and PE among the IBD, UC, and CD cohorts. Odds ratios of potential risk factors were calculated by univariate and multivariate analyses in a nested case-control design. Results Overall, 16 273 patients with IBD were included: 13 585 with UC and 3443 with CD. VTE events occurred in 1.3%, 1.2%, and 1.9% of patients with IBD, UC, and CD, respectively. In patients with IBD, UC, and CD, IRs of VTE were 0.45, 0.40, and 0.64, respectively, IRs of DVT were 0.42, 0.38, and 0.61, respectively, and IRs of PE were 0.07, 0.07, and 0.11, respectively. In patients with IBD, treatment history (immunomodulators), cardiovascular risk (hypertension, high-density lipoprotein or diabetes mellitus, and history of coronary artery disease or heart failure), malignancy, and undergoing major surgery were identified as potential risk factors for VTE in the multivariate analysis, with similar risk factors reported for patients with UC and CD. Conclusions This large study provides insight into the incidence and risk factors for VTE in patients with IBD from Japan.
引用
收藏
页码:5195 / 5205
页数:11
相关论文
共 50 条
  • [31] REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS
    Schreiber, Stefan
    Dignass, Axel
    Peyrin-Biroulet, Laurent
    Mosli, Mahmoud
    Hather, Greg
    Demuth, Dirk
    Blake, Aimee
    Curtis, Rebecca
    Khalid, Javaria Mona
    Loftus, Edward V., Jr.
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S57 - S58
  • [32] Inflammatory Bowel Disease Therapy and Venous Thromboembolism
    Thomas Lambin
    Adam S. Faye
    Jean-Frédéric Colombel
    [J]. Current Treatment Options in Gastroenterology, 2020, 18 (3) : 462 - 475
  • [33] Recurrent Venous Thromboembolism in Inflammatory Bowel Disease
    Novacek, Gottfried
    [J]. PRACTICAL GASTROENTEROLOGY, 2011, 35 (07) : 25 - 29
  • [34] Risk of Venous Thromboembolism With Inflammatory Bowel Disease
    Saleh, Tarek
    Matta, Fadi
    Yaekoub, Abdo Y.
    Danescu, Septimiu
    Stein, Paul D.
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2011, 17 (03) : 254 - 258
  • [35] Disease activity and venous thromboembolism in inflammatory bowel disease
    Ghosh, Tilak
    Ford, Alexander C.
    Everett, Simon
    [J]. LANCET, 2010, 375 (9727): : 1690 - 1690
  • [36] Duration of risk of venous thromboembolism in real-world US surgical patients
    Amin, Alpesh N.
    Lenhart, Greg
    Lin, Jay
    Thompson, Stephen
    Johnston, Stephen
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 31 (03) : 398 - 399
  • [37] REAL-WORLD RISKS OF SURGICAL INTERVENTIONS IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION COHORT ANALYSIS
    Shah, Yash
    Burris, Victoria
    Shah, Vraj P.
    Weber, Andrew T.
    Patel, Dhruvan
    Lichtenstein, Gary R.
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S690 - S690
  • [38] Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease
    Brian Bressler
    Jennifer Jones
    Tracy S. H. In
    Tommy Lan
    Cristian Iconaru
    John K. Marshall
    [J]. Advances in Therapy, 2023, 40 : 4421 - 4439
  • [39] Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease
    Bressler, Brian
    Jones, Jennifer
    In, Tracy S. H.
    Lan, Tommy
    Iconaru, Cristian
    Marshall, John K.
    [J]. ADVANCES IN THERAPY, 2023, 40 (10) : 4421 - 4439
  • [40] Effect of surgical approach on venous thromboembolism in inflammatory bowel disease patients
    Keller, Deborah S.
    Langenfeld, Sean J.
    Lomelin, Daniel E.
    Oleynikov, Dmitry
    Haas, Eric M.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 221 (04) : E59 - E59